A detailed history of Geode Capital Management, LLC transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Geode Capital Management, LLC holds 2,999,935 shares of DVAX stock, worth $37.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,999,935
Previous 3,089,690 2.9%
Holding current value
$37.3 Million
Previous $34.7 Million 3.68%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$10.05 - $11.61 $902,037 - $1.04 Million
-89,755 Reduced 2.9%
2,999,935 $33.4 Million
Q2 2024

Aug 09, 2024

BUY
$10.73 - $12.58 $1.88 Million - $2.2 Million
174,997 Added 6.0%
3,089,690 $34.7 Million
Q1 2024

May 13, 2024

BUY
$11.7 - $14.98 $1.1 Million - $1.41 Million
93,795 Added 3.33%
2,914,693 $36.2 Million
Q4 2023

Feb 13, 2024

BUY
$13.09 - $14.98 $1.57 Million - $1.8 Million
120,062 Added 4.45%
2,820,898 $39.4 Million
Q3 2023

Nov 13, 2023

BUY
$12.64 - $14.99 $2.32 Million - $2.75 Million
183,436 Added 7.29%
2,700,836 $39.9 Million
Q2 2023

Aug 11, 2023

BUY
$9.85 - $13.17 $2 Million - $2.68 Million
203,425 Added 8.79%
2,517,400 $32.5 Million
Q1 2023

May 15, 2023

BUY
$9.44 - $11.88 $913,291 - $1.15 Million
96,747 Added 4.36%
2,313,975 $22.7 Million
Q4 2022

Feb 13, 2023

BUY
$10.27 - $13.29 $817,933 - $1.06 Million
79,643 Added 3.73%
2,217,228 $23.6 Million
Q3 2022

Nov 14, 2022

BUY
$9.93 - $17.44 $599,712 - $1.05 Million
60,394 Added 2.91%
2,137,585 $22.3 Million
Q2 2022

Aug 12, 2022

BUY
$7.45 - $12.83 $651,271 - $1.12 Million
87,419 Added 4.39%
2,077,191 $26.2 Million
Q1 2022

May 13, 2022

BUY
$9.75 - $14.44 $732,858 - $1.09 Million
75,165 Added 3.93%
1,989,772 $21.6 Million
Q4 2021

Feb 11, 2022

BUY
$13.17 - $20.94 $1.33 Million - $2.12 Million
101,297 Added 5.59%
1,914,607 $26.9 Million
Q3 2021

Nov 12, 2021

BUY
$9.16 - $19.83 $427,442 - $925,347
46,664 Added 2.64%
1,813,310 $34.8 Million
Q2 2021

Aug 13, 2021

BUY
$7.25 - $10.99 $514,539 - $779,971
70,971 Added 4.19%
1,766,646 $17.4 Million
Q1 2021

May 12, 2021

BUY
$4.57 - $11.18 $668,074 - $1.63 Million
146,187 Added 9.43%
1,695,675 $16.7 Million
Q4 2020

Feb 12, 2021

BUY
$3.73 - $5.6 $95,223 - $142,962
25,529 Added 1.68%
1,549,488 $6.9 Million
Q3 2020

Nov 13, 2020

BUY
$4.32 - $11.7 $545,037 - $1.48 Million
126,166 Added 9.03%
1,523,959 $6.58 Million
Q2 2020

Aug 13, 2020

BUY
$2.94 - $9.1 $533,398 - $1.65 Million
181,428 Added 14.92%
1,397,793 $12.4 Million
Q1 2020

May 14, 2020

BUY
$2.27 - $6.2 $149,849 - $409,280
66,013 Added 5.74%
1,216,365 $4.29 Million
Q4 2019

Feb 13, 2020

BUY
$3.46 - $6.93 $206,427 - $413,450
59,661 Added 5.47%
1,150,352 $6.58 Million
Q3 2019

Nov 12, 2019

BUY
$2.69 - $4.85 $817,275 - $1.47 Million
303,820 Added 38.61%
1,090,691 $3.9 Million
Q2 2019

Aug 14, 2019

BUY
$3.65 - $7.89 $347,757 - $751,727
95,276 Added 13.78%
786,871 $3.14 Million
Q1 2019

May 14, 2019

BUY
$7.08 - $12.09 $287,745 - $491,361
40,642 Added 6.24%
691,595 $5.06 Million
Q4 2018

Feb 13, 2019

BUY
$8.14 - $13.28 $464,647 - $758,048
57,082 Added 9.61%
650,953 $5.96 Million
Q3 2018

Nov 13, 2018

BUY
$11.85 - $16.0 $483,799 - $653,232
40,827 Added 7.38%
593,871 $7.36 Million
Q2 2018

Aug 14, 2018

BUY
$15.15 - $20.75 $859,792 - $1.18 Million
56,752 Added 11.44%
553,044 $8.43 Million
Q1 2018

May 15, 2018

BUY
$14.65 - $19.9 $158,967 - $215,934
10,851 Added 2.24%
496,292 $9.85 Million
Q4 2017

Feb 13, 2018

BUY
$17.3 - $24.08 $25,569 - $35,590
1,478 Added 0.31%
485,441 $9.08 Million
Q3 2017

Nov 14, 2017

BUY
$15.2 - $21.5 $379,270 - $536,468
24,952 Added 5.44%
483,963 $10.4 Million
Q2 2017

Aug 14, 2017

BUY
N/A
459,011
459,011 $4.43 Million

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.57B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.